Iovance Biotherapeutics Shares Drop 34% Following Phase 2 Amtagvi Data for Lung Cancer
Iovance Biotherapeutics (IOVA) shares fell approximately 34% in Thursday trading following the release of phase 2 clinical trial data for its therapy, Amtagvi (lifileucel). The study focused on two cohorts of patients with previously treated non-squamous non-small-cell lung cancer. The market reaction reflects investor concerns regarding the efficacy or clinical profile presented in the latest data cutoff. While Amtagvi is a key part of Iovance's pipeline, this specific setback for its lung cancer application has significantly impacted the company's valuation.
Tickers: $IOVA
Topics: clinical trial data lung cancer oncology stock price drop